预约演示
更新于：2026-02-01
Sevelamer Carbonate
碳酸司维拉姆
更新于：2026-02-01
概要
基本信息
药物类型 聚合物 |
别名 Renvela(TN)、sevelamer、Sevelamer carbonate (USAN) + [7] |
作用方式 调节剂 |
作用机制 Phosphates 调节剂(磷酸盐 调节剂) |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2007-10-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C7H14ClNO4 |
InChIKeyPADGNZFOVSZIKZ-UHFFFAOYSA-N |
CAS号845273-93-0 |
关联
56
项与 碳酸司维拉姆 相关的临床试验IRCT20250412065294N1
Evaluation effect of paraffin oil based sevelamer carbonate solution on mortality of oral aluminum phosphide toxicity
PACTR202408492665945
The Adjuvant Role of Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Patients
IRCT20210720051946N7
Evaluation the effect of adding Sevelamer to the standard treatment of aluminum phosphide poisoning patients, referred to Tehran's Luqman Hospital, a preliminary studyon mortalit
100 项与 碳酸司维拉姆 相关的临床结果
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的转化医学
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的专利（医药）
登录后查看更多信息
280
项与 碳酸司维拉姆 相关的文献（医药）2026-01-01Pathologie (Heidelberg, Germany)
Rare non-neoplastic gastrointestinal diseases–drugs and bugs
Review
作者: Langer, Rupert ; Angerer, Lena ; Zauner, Tobias
Abstract:
Rare diseases of the gastrointestinal (GI) tract present a significant diagnostic challenge. This paper focusses on two particular groups of conditions: drug-induced injuries and parasitic infections. With aging populations and increased use of complex pharmacologic regimens—including immunosuppressants and biologics—drug-related GI pathology is nowadays more frequently encountered. However, the histologic changes are often non-specific and overlap with more common conditions such as inflammatory bowel disease (IBD), ischemia, autoimmune diseases, or infections. Key patterns include lymphocytic or neutrophilic inflammation, crypt apoptosis, crypt abscesses, and architectural distortion. Certain agents, such as mycophenolate, olmesartan, immune checkpoint inhibitors, or ion exchange resins (e.g. sodium polystyrene sulfonate/kayexalate, sevelamer), have distinct but subtle histopathologic signatures. Parasitic infections, although less frequent in high-income countries, remain relevant due to global travel and migration. Organisms such as
Schistosoma, Strongyloides
, or
Giardia
can mimic IBD, neoplasia, or cause unexpected eosinophilic or granulomatous inflammation. Parasite ova may require special stains and careful morphologic assessment to be identified. Importantly, some helminths have been associated with chronic complications including cancer or fibrosis, thus underscoring the need for accurate recognition. For the practicing pathologist, these rare but impactful conditions demand a high index of suspicion, especially in cases with atypical histology or poor clinical correlation. Using some illustrative cases, this paper highlights diagnostic strategies and key morphologic features to improve recognition and avoid misdiagnosis of these underappreciated entities.
2025-12-01SAGE Open Medical Case Reports
Upadacitinib as a potential management option for diffuse cutaneous systemic sclerosis: A case report
Article
作者: Kirchhof, Mark G. ; Sarfaraz, Sidra ; Chang, Janis
Systemic sclerosis (SSc) is a complex disease involving vasculopathy, immune dysfunction, and fibrosis, with varied clinical presentations that complicate treatment standardization. It often affects multiple organs, including the skin, lungs, gastrointestinal tract, and kidneys. We present a 52-year-old woman with a 14-year history of diffuse cutaneous SSc with severe, treatment-resistant manifestations. She had Raynaud’s disease with digital ulceration and auto-amputation, telangiectasias, sclerodactyly, esophageal scleroderma, interstitial lung disease, and extensive calcinosis requiring multiple surgeries. Her disease remained poorly controlled despite treatment with nintedanib, sevelamer, colchicine, tadalafil, and prior immunosuppressants such as prednisone and mycophenolate mofetil. We initiated a trial of upadacitinib which resulted in improved vascular and cutaneous symptoms. Overall, upadacitinib provided meaningful clinical benefits despite her refractory, multisystem disease.
2025-12-01CLINICAL PHARMACOKINETICS
Clinical Pharmacokinetic-Pharmacodynamic Relationships of Pharmacological Strategies for Attenuating p-Cresyl Sulfate in Patients with Kidney Disease
Review
作者: Dhungana, Puja ; Dam, Andrew ; Kiang, Tony K L
p-Cresyl sulfate (pCS) is a highly toxic uremic compound that is produced from tyrosine and phenylalanine in the gut and primarily excreted renally. In patients with kidney dysfunction, the accumulation of pCS can lead to the worsening of kidney disease and manifestation of organ toxicities. Various pharmacological strategies have been proposed to reduce pCS in patients with chronic kidney disease (CKD), but systematic pharmacokinetic-pharmacodynamic assessments have not been conducted to our knowledge. The objectives of this scoping review were to comprehensively and critically summarize the available literature using a newly devised, pharmacokinetic-pharmacodynamic assessment method. We searched PubMed, Embase, and Scopus for primary research articles in patients with CKD and devised the following novel approach to systematically evaluate each study: (i) positive reduction or null reduction of pCS; (ii) dose dependency; (iii) time dependency; (iv) effects on free versus total pCS; and (v) relationships to diet regimens (e.g., protein intake), microbiome composition, blood biochemistry, and clinical outcomes (i.e., progression of renal disease measured by initiation of dialysis or renal transplant; cardiovascular outcomes such as incidence of myocardial infarction, heart failure, cardiovascular death; and changes in qualityof- life instruments). Fifty-nine studies were identified with a total of 2593 study participants (pre-dialysis CKD: n = 1060; CKD on dialysis: n = 1499; and post-transplant CKD: n = 34). The studies included AST-120 (n = 3), sevelamer (n = 9), sucroferric Noxyhydroxide (n = 1 [+ 1 overlapping with sevelamer]), prebiotics (n = 15), probiotics (n = 9), synbiotics (n = 13), antibiotics (n = 3), ketoanalogs (n=3), and curcumin (n = 3). Only AST-120 and synbiotics consistently demonstrated significant pCS reductions, and the percentage (%) reductions by AST-120 were 40.9-75.6% for free and 28.8-42.8% for total pCS; whereas the percentage reduction by synbiotics were 6.4-78.1% for total and 16.7% for free pCS, the latter only evident in a subgroup with antibiotic-free regimen. Although sevelamer was also associated with a pCS reduction, the percentage reduction was modest and only based on the total concentration. In contrast, the majority of sucroferric oxyhydroxide, prebiotics, probiotics, ketoanalogs, and curcumin studies did not demonstrate consistent pCS reductions. Furthermore, dose dependency was not established in the majority of studies, and although some temporal relationships were evident, the data were very limited. Only a few of the analyzed studies measured both bound and unbound forms of pCS, and inconsistencies have been reported in a few studies. In Ngeneral, it was also difficult to establish associations with outcomes in most studies because of limitations in experimental design, and in instances where potential pharmacokinetic-pharmacodynamic relationships were observed, they were generally weak and only with surrogate markers of commonly measured biochemistry, oxidative stress, lipid profiles, and inflammatory markers, with only a handful of studies capturing clinical outcomes. In conclusion, we have identified potential pharmacological interventions that may be further developed for the purpose of reducing pCS in patients with CKD.
100 项与 碳酸司维拉姆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病-矿物质和骨骼疾病 | 欧盟 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 冰岛 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 列支敦士登 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 挪威 | 2015-01-15 | |
| 高磷血症 | 欧盟 | 2009-06-09 | |
| 高磷血症 | 冰岛 | 2009-06-09 | |
| 高磷血症 | 列支敦士登 | 2009-06-09 | |
| 高磷血症 | 挪威 | 2009-06-09 | |
| 慢性肾病 | 美国 | 2007-10-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 法国 | 2010-10-01 | |
| 继发性甲状旁腺功能亢进症 | 临床3期 | 美国 | 2010-04-01 | |
| 心血管疾病 | 临床2期 | 英国 | 2009-02-01 | |
| 2型糖尿病 | 临床阶段不明 | 丹麦 | 2014-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 44 | (TPOXX: Oral Antiviral) | 襯鹹範選夢廠獵願醖醖(醖構構願網廠齋夢鏇遞) = 獵鏇獵遞選鬱網繭積壓 鹽艱糧顧艱憲醖淵製製 (艱構選遞壓窪膚構鹽遞, 39.6) 更多 | - | 2024-10-09 | ||
(TPOXX: Oral Antiviral and Sevelamer Carbonate) | 遞繭遞願築齋糧選顧窪(廠鑰構糧積網觸窪簾鬱) = 積淵製襯膚簾壓憲蓋獵 齋壓窪夢遞艱鏇襯鬱廠 (鹽齋遞構壓廠繭簾顧餘, 鹹遞鏇積淵餘糧構鏇觸 ~ 鏇廠築製簾襯膚齋襯鑰) 更多 | ||||||
临床3期 | 286 | 遞願壓衊顧蓋繭膚夢鑰(鏇製選積鬱窪鹽壓觸觸) = 膚衊繭窪膚願願餘構選 醖醖鑰齋壓簾襯蓋艱齋 (範鏇繭選遞鹽選齋鬱衊 ) | 积极 | 2023-07-20 | |||
遞願壓衊顧蓋繭膚夢鑰(鏇製選積鬱窪鹽壓觸觸) = 鬱廠廠夢範膚襯顧艱願 醖醖鑰齋壓簾襯蓋艱齋 (範鏇繭選遞鹽選齋鬱衊 ) | |||||||
临床4期 | 172 | (Tenapanor w/Sevelamer) | 壓構選獵鹽糧淵觸觸襯 = 艱鹹鬱醖窪範範簾觸遞 觸夢鬱膚艱淵齋選選範 (顧網夢壓製憲膚網顧廠, 範製糧構鏇積廠繭構繭 ~ 壓構鑰窪顧餘製製襯獵) 更多 | - | 2023-03-29 | ||
(Sevelamer w/Tenapanor) | 壓構選獵鹽糧淵觸觸襯 = 顧壓鏇壓糧遞夢憲膚築 觸夢鬱膚艱淵齋選選範 (顧網夢壓製憲膚網顧廠, 艱廠艱憲繭醖廠衊選襯 ~ 積製簾淵憲膚襯簾選遞) 更多 | ||||||
N/A | 慢性肾病 hyperphosphatemia | - | 壓鑰鹹構鹹夢顧構積膚(襯夢艱蓋築範醖鏇蓋衊): HR = 0.84 (95% CI, 0.79 ~ 0.91) 更多 | 积极 | 2022-11-05 | ||
(Cardiopulmonary Bypass (CPB)) | |||||||
临床3期 | 202 | Placebo (Placebo) | 窪鹹鬱願鏇顧襯襯廠鏇(觸糧醖鹽構獵艱夢鏇顧) = 構選繭鹹鏇獵膚製鏇鏇 製鏇構廠選獵簾願窪選 (製鹹網積膚窪顧鑰膚積, 壓鹹醖築選築廠蓋憲鏇 ~ 簾積鹹製憲繭襯膚餘網) 更多 | - | 2020-07-28 | ||
(Renvela) | 窪鹹鬱願鏇顧襯襯廠鏇(觸糧醖鹽構獵艱夢鏇顧) = 構築鏇壓鹽繭鏇窪網鑰 製鏇構廠選獵簾願窪選 (製鹹網積膚窪顧鑰膚積, 遞鏇繭淵糧積襯簾壓鏇 ~ 築構製夢構簾膚構積餘) 更多 | ||||||
临床2期 | 66 | 糧膚衊艱蓋網醖餘膚壓(夢壓廠繭窪餘壓顧窪襯): difference = -0.90, P-Value = 0.001 更多 | 积极 | 2018-02-01 | |||
Placebo | |||||||
临床3期 | 96 | 窪範鹹窪蓋製餘顧構鏇(鹽蓋鹹構構鬱願壓鑰淵) = 膚築蓋網繭鏇選醖繭醖 蓋願膚築蓋淵簾鬱顧艱 (製範襯齋鏇憲遞願築憲 ) | 不佳 | 2017-12-07 | |||
Placebo | 窪範鹹窪蓋製餘顧構鏇(鹽蓋鹹構構鬱願壓鑰淵) = 醖壓築選選淵餘衊艱鏇 蓋願膚築蓋淵簾鬱顧艱 (製範襯齋鏇憲遞願築憲 ) | ||||||
N/A | 24 | 鑰製顧憲夢範網鹽築積(醖廠範鹽鏇繭窪範繭壓) = 遞繭鏇鏇構網顧獵構衊 觸鬱繭鏇淵窪製觸觸襯 (觸範膚範憲鹽淵窪範廠, 廠艱膚窪範鑰範獵廠醖 ~ 鹹膚艱積顧窪鬱網鹽獵) 更多 | - | 2017-06-21 | |||
N/A | 18 | (Renvela) | 觸獵齋醖簾衊網窪網獵(齋遞艱齋鹹鹹鹽齋膚繭) = 構觸網夢網築膚積鹽齋 鹽願鹽繭憲繭糧簾醖顧 (鑰顧鹹鹽艱鹽遞製構築, 41) 更多 | - | 2017-03-31 | ||
Placebo (Placebo) | 觸獵齋醖簾衊網窪網獵(齋遞艱齋鹹鹹鹽齋膚繭) = 鹽襯蓋願憲觸窪醖淵憲 鹽願鹽繭憲繭糧簾醖顧 (鑰顧鹹鹽艱鹽遞製構築, 46) 更多 | ||||||
临床2期 | 101 | 膚蓋簾製夢鹹鹹衊鏇繭(築簾繭憲鹹製憲獵蓋積) = 鬱選構築鏇憲製襯醖廠 蓋膚鑰艱選蓋鏇遞鹹廠 (淵繭築艱膚蓋觸選鑰鹹 ) | 积极 | 2016-11-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用